ADC Market Will Remain Hot in Oncology, Reaching $30B by 2028: Report

The antibody-drug conjugate market has been one of the hottest sectors in the biopharma industry as of late. Big players such as Pfizer, AbbVie, AstraZeneca, Merck and others are shelling out billions of dollars to acquire or license the breakthrough technology in targeted cancer therapy. This trend will continue over the next few years with the category worth nearly $30 billion by 2028, according to a new report from market intelligence firm Evaluate.